PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.
暂无分享，去创建一个
Martin C. Müller | M. Baccarani | J. Dipersio | H. Kantarjian | F. Haluska | J. Cortes | C. Chuah | D. DeAngelo | R. Paquette | M. Talpaz | J. Pinilla-Ibarz | H. Khoury | C. Gambacorti-Passerini | Dong-Wook Kim | P. Coutre | F. Nicolini | C. Turner | J. Apperley | E. Abruzzese | D. Réa